Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-Cell responses to the tumor-specific antigen NY-ESO-1

被引:55
|
作者
Le Gal, FA
Ayyoub, M
Dutoit, V
Widmer, V
Jäger, E
Cerottini, JC
Dietrich, PY
Valmori, D
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Med, Ludwig Inst,Clin Trial Ctr,Div Med Oncol, New York, NY 10032 USA
[2] Univ Hosp Geneva, Div Oncol, Lab Tumor Immunol, Geneva, Switzerland
[3] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[4] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland
关键词
T-cell receptor; repertoire; tumor immunity; vaccination;
D O I
10.1097/01.cji.0000161398.34701.26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epilope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines. but they are heterogeneous in terms of functional avidity and tumor reactivity, The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may rail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity.
引用
收藏
页码:252 / 257
页数:6
相关论文
共 50 条
  • [31] Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
    Klein, Oliver
    Davis, Ian D.
    McArthur, Grant A.
    Chen, Li
    Haydon, Andrew
    Parente, Phillip
    Dimopoulos, Nektaria
    Jackson, Heather
    Xiao, Kun
    Maraskovsky, Eugene
    Hopkins, Wendie
    Stan, Rodica
    Chen, Weisan
    Cebon, Jonathan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (04) : 507 - 518
  • [32] Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
    Oliver Klein
    Ian D. Davis
    Grant A. McArthur
    Li Chen
    Andrew Haydon
    Phillip Parente
    Nektaria Dimopoulos
    Heather Jackson
    Kun Xiao
    Eugene Maraskovsky
    Wendie Hopkins
    Rodica Stan
    Weisan Chen
    Jonathan Cebon
    Cancer Immunology, Immunotherapy, 2015, 64 : 507 - 518
  • [33] Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response
    Khong, Hiep
    Volmari, Annika
    Sharma, Meenu
    Dai, Zhimin
    Imo, Chinonye S.
    Hailemichael, Yared
    Singh, Manisha
    Moore, Derek T.
    Xiao, Zhilan
    Huang, Xue-fei
    Horvath, Thomas D.
    Hawke, David H.
    Overwijk, Willem W.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (10): : 3464 - 3474
  • [34] Oral Vaccination with Attenuated Salmonella enterica Strains Encoding T-Cell Epitopes from Tumor Antigen NY-ESO-1 Induces Specific Cytotoxic T-Lymphocyte Responses
    Meng, Jia-Zi
    Dong, Yu-Jun
    Huang, He
    Li, Shuang
    Zhong, Yi
    Liu, Shu-Lin
    Wang, Yue-Dan
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (06) : 889 - 894
  • [35] ANALYSIS OF CD8+ T-CELL RESPONSES TO AFP, GLYPICAN-3, MAGE-A1 AND NY-ESO-1 IN PATIENTS WITH HEPATOCELLULAR CARCINOMA REVEALS A CLEAR HIERARCHY AND IMMUNODOMINANCE
    Flecken, T.
    Breous, E.
    Neumann-Haefelin, C.
    Spangenberg, H. C.
    Drognitz, O.
    Blum, H. E.
    Thimme, R.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S88 - S88
  • [36] Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma
    Reynolds, SR
    Zeleniuch-Jacquotte, A
    Shapiro, RL
    Roses, DF
    Harris, MN
    Johnston, D
    Bystryn, JC
    CLINICAL CANCER RESEARCH, 2003, 9 (02) : 657 - 662
  • [37] NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors
    Maraskovsky, E
    Sjölander, S
    Drane, DP
    Schnurr, M
    Le, TTT
    Mateo, L
    Luft, T
    Masterman, KA
    Tai, TY
    Chen, QY
    Green, S
    Sjölander, A
    Pearse, MJ
    Lemonnier, FA
    Chen, WS
    Cebon, J
    Suhrbier, A
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2879 - 2890
  • [38] Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+T Cells
    Manco, Roberta
    D'Apice, Luciana
    Trovato, Maria
    Lione, Lucia
    Salvatori, Erika
    Pinto, Eleonora
    Compagnone, Mirco
    Aurisicchio, Luigi
    De Berardinis, Piergiuseppe
    Sartorius, Rossella
    VIRUSES-BASEL, 2023, 15 (03):
  • [39] CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients
    Gnjatic, S
    Jäger, E
    Chen, WS
    Altorki, NK
    Matsuo, M
    Lee, SY
    Chen, QY
    Nagata, Y
    Atanackovic, D
    Chen, YT
    Ritter, G
    Cebon, J
    Knuth, A
    Old, LJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (18) : 11813 - 11818
  • [40] LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses
    Ta, Hieu Minh
    Roy, Dia
    Zhang, Keman
    Alban, Tyler
    Juric, Ivan
    Dong, Juan
    Parthasarathy, Prerana B.
    Patnaik, Sachin
    Delaney, Elizabeth
    Gilmour, Cassandra
    Zakeri, Amin
    Shukla, Nidhi
    Rupani, Amit
    Phoon, Yee Peng
    Liu, Caini
    Avril, Stefanie
    Gastman, Brian
    Chan, Timothy
    Wang, Li Lily
    SCIENCE IMMUNOLOGY, 2024, 9 (95)